Daniel A. Schupack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel A. Schupack has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Karthik Ravi
Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA
3 shared publicationsCrystal Lavey
Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA
2 shared publicationsDavid A Katzka
Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA
2 shared publicationsDavid A. Katzka
Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA
2 shared publicationsDebra M. Geno
Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN USA
2 shared publicationsJeffrey A Alexander
Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA
2 shared publications
Latest Publications
- Open Access
Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer
Background and aims: Aberrations in telomere length can have important implications in cancer. Using a cohort of 1007 patients, we investigated whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival. We also investigated whether some telomere maintenance genes are associated with survival in these patients. Methods: The Biobank for Gastrointestinal Health Research (BGHR), an ongoing project involving collection of biospecimens at the Mayo Clinic, was utilized to obtain data from patients diagnosed with stage II or III CRC. Blood samples were collected prior to chemotherapy/radiation and DNA was extracted for measuring median LTL. The main outcome measures were overall survival (OS) and disease-free survival (DFS) by disease stage. Results: A significant inverse relationship was observed with patient age and LTL (spearman correlation coefficient (r) = −0.48, 95%; p = 1.13 × 10−58). Females had significantly longer LTL than males (p = 3.97 × 10−5). The rs1317082 SNP in the TERC gene was significantly associated with both OS and DFS in combined stage II and stage III patients (p = 0.017 and p = 0.023, respectively). A statistically significant association of the OBFC1 SNP (rs9419958) was observed for OS for the combined stage II and stage III patients (p = 0.016). Importantly, LTL was significantly associated with both OS and DFS (p = 0.008 and 0.044 respectively) in combined stage II and stage III patients. Conclusions: Our results show that LTL is predictive of OS and DFS for stage II and III CRC patients, particularly over a longer follow-up, extending beyond five years after a diagnosis of CRC, and certain SNPs in genes involved in telomere maintenance are significantly associated with patient outcomes, independent of telomere length.
Open AccessLeukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer
Background and aims: Aberrations in telomere length can have important implications in cancer. Using a cohort of 1007 patients, we investigated whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival. We also investigated whether some telomere maintenance genes are associated with survival in these patients. Methods: The Biobank for Gastrointestinal Health Research (BGHR), an ongoing project involving collection of biospecimens at the Mayo Clinic, was utilized to obtain data from patients diagnosed with stage II or III CRC. Blood samples were collected prior to chemotherapy/radiation and DNA was extracted for measuring median LTL. The main outcome measures were overall survival (OS) and disease-free survival (DFS) by disease stage. Results: A significant inverse relationship was observed with patient age and LTL (spearman correlation coefficient (r) = −0.48, 95%; p = 1.13 × 10−58). Females had significantly longer LTL than males (p = 3.97 × 10−5). The rs1317082 SNP in the TERC gene was significantly associated with both OS and DFS in combined stage II and stage III patients (p = 0.017 and p = 0.023, respectively). A statistically significant association of the OBFC1 SNP (rs9419958) was observed for OS for the combined stage II and stage III patients (p = 0.016). Importantly, LTL was significantly associated with both OS and DFS (p = 0.008 and 0.044 respectively) in combined stage II and stage III patients. Conclusions: Our results show that LTL is predictive of OS and DFS for stage II and III CRC patients, particularly over a longer follow-up, extending beyond five years after a diagnosis of CRC, and certain SNPs in genes involved in telomere maintenance are significantly associated with patient outcomes, independent of telomere length.
- 3 July 2022
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 36 (1)
Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound
Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3 mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (<50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.
- 3 July 2022
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 36 (1)
Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound
Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3 mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (<50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.
- Open Access
- 23 October 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (6) , 272-280
Stable interval bone density in patients with eosinophilic oesophagitis on topical steroids
Objective This study was undertaken to evaluate the effects of maintenance topical steroids (TS) used for treatment in adult patients with eosinophilic esophagitis (EoE) on bone health. Patients and Methods We performed a retrospective review of patients with EoE (≥15 eosinophils/HPF on esophageal biopsy) who were seen in the Esophageal Clinic between January 1, 2013 and May 31, 2020, treated with maintenance TS for ≥one year and underwent bone health evaluation. Dual energy X‐ray absorptiometry (DEXA) scans were obtained during steroid induction therapy, with follow up studies obtained at least one year later. Demographic, laboratory, radiographic, endoscopic and histologic findings were reviewed. Results 21 patients had baseline and follow up DEXA scans (mean age of 44 years, slight male predominance (61.9%)). TS regimens included Budesonide‐Rincinol gel and Budesonide capsules mixed into slurry (induction dose range from 1.5 mg‐6 mg total daily, maintenance dose range from 0.5‐6 mg total daily). Mean follow up between initial and final DEXA was 707±391 days. Mean (±SD) baseline T‐score, Z‐score, and BMD (from spine, hips and femurs) (g/cm2) was ‐0.3±1.09, ‐0.06±0.93, and 1.05±0.15 respectively. Mean (±SD) change in bone mineral density was +0.38%±1.5% with mean change in absolute BMD of ‐0.01±0.04 g/cm2 (p=0.3). One patient progressed from normal BMD to osteopenia and none from osteopenia to osteoporosis. Conclusion Chronic maintenance steroid therapy in this pilot study does not appear to induce significant change in BMD in patients with EoE. Larger and longer trials are needed to validate these conclusions.
- 23 October 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (6) , 272-280
Open AccessStable interval bone density in patients with eosinophilic oesophagitis on topical steroids
Objective This study was undertaken to evaluate the effects of maintenance topical steroids (TS) used for treatment in adult patients with eosinophilic esophagitis (EoE) on bone health. Patients and Methods We performed a retrospective review of patients with EoE (≥15 eosinophils/HPF on esophageal biopsy) who were seen in the Esophageal Clinic between January 1, 2013 and May 31, 2020, treated with maintenance TS for ≥one year and underwent bone health evaluation. Dual energy X‐ray absorptiometry (DEXA) scans were obtained during steroid induction therapy, with follow up studies obtained at least one year later. Demographic, laboratory, radiographic, endoscopic and histologic findings were reviewed. Results 21 patients had baseline and follow up DEXA scans (mean age of 44 years, slight male predominance (61.9%)). TS regimens included Budesonide‐Rincinol gel and Budesonide capsules mixed into slurry (induction dose range from 1.5 mg‐6 mg total daily, maintenance dose range from 0.5‐6 mg total daily). Mean follow up between initial and final DEXA was 707±391 days. Mean (±SD) baseline T‐score, Z‐score, and BMD (from spine, hips and femurs) (g/cm2) was ‐0.3±1.09, ‐0.06±0.93, and 1.05±0.15 respectively. Mean (±SD) change in bone mineral density was +0.38%±1.5% with mean change in absolute BMD of ‐0.01±0.04 g/cm2 (p=0.3). One patient progressed from normal BMD to osteopenia and none from osteopenia to osteoporosis. Conclusion Chronic maintenance steroid therapy in this pilot study does not appear to induce significant change in BMD in patients with EoE. Larger and longer trials are needed to validate these conclusions.
- 12 March 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (2) , 503-510
Effect of Maintenance Therapy for Eosinophilic Esophagitis on Need for Recurrent Dilation
Background Eosinophilic esophagitis is an inflammatory condition in which eosinophil infiltration leads to esophageal remodeling and stricturing, with dilation therapy often needed. Achieving histologic remission reduces the need for repeat dilation, although little is known about the effects of long-term maintenance therapy. Aims To further assess the relationship between short-term histologic remission and maintenance therapy on need for repeat dilation in eosinophilic esophagitis. Methods A total of 77 patients with eosinophilic esophagitis (59.7% male; mean age 41.6 years) seen at a single medical center from June 2000 to August 2017 were included. Information on history of dilation and therapy [proton pump inhibitors (PPIs), steroids, elimination diet] was collected. Mean follow-up was 164 weeks. Fifty-one patients achieved histologic remission and 42 of these remained on maintenance therapy (23 PPIs, 14 topical steroids, and 5 dietary therapy). Standard phone interview was completed in cases with lack of follow-up. Only patients who underwent esophageal dilation to ≥ 17 mm were included. Results A significantly lower proportion of patients on maintenance therapy required repeat dilation (12/42) compared with patients not on maintenance therapy (8/9) (hazard ratio 0.12; p < 0.001). Of patients who received maintenance therapy, 9.1% required re-dilation. The difference in need for repeat dilation in patients who achieved histologic remission on therapy (14/26) versus those who did not (20/51) was not significant (hazard ratio 1.34; p = 0.45). Conclusion In a retrospective analysis of patients with eosinophilic esophagitis, we found that a significantly lower proportion who received maintenance therapy (PPIs, steroids, or dietary exclusions) required repeat dilation.
- 12 March 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (2) , 503-510
Effect of Maintenance Therapy for Eosinophilic Esophagitis on Need for Recurrent Dilation
Background Eosinophilic esophagitis is an inflammatory condition in which eosinophil infiltration leads to esophageal remodeling and stricturing, with dilation therapy often needed. Achieving histologic remission reduces the need for repeat dilation, although little is known about the effects of long-term maintenance therapy. Aims To further assess the relationship between short-term histologic remission and maintenance therapy on need for repeat dilation in eosinophilic esophagitis. Methods A total of 77 patients with eosinophilic esophagitis (59.7% male; mean age 41.6 years) seen at a single medical center from June 2000 to August 2017 were included. Information on history of dilation and therapy [proton pump inhibitors (PPIs), steroids, elimination diet] was collected. Mean follow-up was 164 weeks. Fifty-one patients achieved histologic remission and 42 of these remained on maintenance therapy (23 PPIs, 14 topical steroids, and 5 dietary therapy). Standard phone interview was completed in cases with lack of follow-up. Only patients who underwent esophageal dilation to ≥ 17 mm were included. Results A significantly lower proportion of patients on maintenance therapy required repeat dilation (12/42) compared with patients not on maintenance therapy (8/9) (hazard ratio 0.12; p < 0.001). Of patients who received maintenance therapy, 9.1% required re-dilation. The difference in need for repeat dilation in patients who achieved histologic remission on therapy (14/26) versus those who did not (20/51) was not significant (hazard ratio 1.34; p = 0.45). Conclusion In a retrospective analysis of patients with eosinophilic esophagitis, we found that a significantly lower proportion who received maintenance therapy (PPIs, steroids, or dietary exclusions) required repeat dilation.
- Open Access
- 1 May 2019
- Published by Wiley in United European Gastroenterology Journal
- Vol. 7 (4) , 548-556
The evolution of treatment and complications of esophageal food impaction
Background Esophageal food impaction is relatively common and increasing over time. Treatment ranges from medications to invasive endoscopic therapies. The endoscopic push technique has been advised...
- 1 May 2019
- Published by Wiley in United European Gastroenterology Journal
- Vol. 7 (4) , 548-556
Open AccessThe evolution of treatment and complications of esophageal food impaction
Background Esophageal food impaction is relatively common and increasing over time. Treatment ranges from medications to invasive endoscopic therapies. The endoscopic push technique has been advised...
- 23 May 2017
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 29 (10) , 1-9
The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry
Background: Although major manometric abnormalities, the significance of esophagogastric junction outflow obstruction (EGJOO) and hypercontractile esophagus (HE) is poorly understood. We sought to determine long term outcomes for EGJOO and HE.Methods: High‐resolution impedance manometry (HRIM) studies conducted from 5/30/2012 to 8/1/2014 consistent with EGJOO and HE and normal studies from 5/30/12 to 11/1/12 were identified. Standardized follow up was conducted with a phone survey utilizing the impact dysphagia questionnaire (IDQ‐10).Key Results: 56 EGJOO, 40 HE patients and 33 controls were identified. Structural evaluation with EGD and esophagram did not differ among groups. Use of opiates in EGJOO (P<.05) and of anticholinergics in EGJOO and HE patients was more prevalent than in controls (P<.005). Dysphagia was more common in EGJOO (P<.05) and chest pain more common in HE (P<.005) at presentation. While HE patients were more likely to be symptomatic (P<.05), the majority of EGJOO and HE patients overall were asymptomatic at a mean 2.8 years follow up without medical or procedural intervention in the majority (72.5%). Symptom persistence at follow up was predicted by maximum distal contractile integral (DCI) and IRP in both EGJOO and HE (P<.05).Conclusions & Inferences: The majority of patients with EGJOO and HE appear to have a benign clinical course similar to controls in the absence of specific treatment. However, the combination of abnormal IRP and DCI in both HE and EGJOO appears to discriminate an important subset of patients who may benefit from treatment. Further refinement of manometric criteria may therefore provide more useful clinical definitions of EGJOO and HE.
- 23 May 2017
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 29 (10) , 1-9
The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry
Background: Although major manometric abnormalities, the significance of esophagogastric junction outflow obstruction (EGJOO) and hypercontractile esophagus (HE) is poorly understood. We sought to determine long term outcomes for EGJOO and HE.Methods: High‐resolution impedance manometry (HRIM) studies conducted from 5/30/2012 to 8/1/2014 consistent with EGJOO and HE and normal studies from 5/30/12 to 11/1/12 were identified. Standardized follow up was conducted with a phone survey utilizing the impact dysphagia questionnaire (IDQ‐10).Key Results: 56 EGJOO, 40 HE patients and 33 controls were identified. Structural evaluation with EGD and esophagram did not differ among groups. Use of opiates in EGJOO (P<.05) and of anticholinergics in EGJOO and HE patients was more prevalent than in controls (P<.005). Dysphagia was more common in EGJOO (P<.05) and chest pain more common in HE (P<.005) at presentation. While HE patients were more likely to be symptomatic (P<.05), the majority of EGJOO and HE patients overall were asymptomatic at a mean 2.8 years follow up without medical or procedural intervention in the majority (72.5%). Symptom persistence at follow up was predicted by maximum distal contractile integral (DCI) and IRP in both EGJOO and HE (P<.05).Conclusions & Inferences: The majority of patients with EGJOO and HE appear to have a benign clinical course similar to controls in the absence of specific treatment. However, the combination of abnormal IRP and DCI in both HE and EGJOO appears to discriminate an important subset of patients who may benefit from treatment. Further refinement of manometric criteria may therefore provide more useful clinical definitions of EGJOO and HE.